Primary research

Effect of 5-azacytidine and galectin-1 on growth and differentiation of the human b lymphoma cell line bl36

Florence Poirier1, Philippe Bourin2, Dominique Bladier1,3, Raymonde Joubert-Caron1 and Michel Caron*1,3

Address: 1Biochimie des Protéines et Protéomique, U.F.R. SMBH, Léonard de Vinci, Université Paris 13, 74 rue Marcel Cochin, F-93017 Bobigny cedex, France; 2Laboratoire d’Immunologie Cellulaire, Centre de Transfusion Sanguine des Armées, F-92140 Clamart, France; and 3Laboratoire Central de Biochimie, Hôpital Avicenne, F-93009 Bobigny cedex, France

E-mail: Florence Poirier - caron@smbh.univ-paris13.fr; Philippe Bourin - caron@smbh.univ-paris13.fr; Dominique Bladier - caron@smbh.univ-paris13.fr; Raymonde Joubert-Caron - caron@smbh.univ-paris13.fr; Michel Caron* - caron@smbh.univ-paris13.fr

*Corresponding author

Abstract

Background: 5-AzaCytidine (AzaC) is a DNA demethylating drugs that has been shown to inhibit cell growth and to induce apoptosis in certain cancer cells. Induced expression of the galectin1 (Gal1) protein, a galactoside-binding protein distributed widely in immune cells, has been described in cultured hepatoma-derived cells treated with AzaC and this event may have a role in the effect of the drug. According to this hypothesis, we investigated the effect of AzaC and Gal1 on human lymphoid B cells phenotype.

Methods: The effect of AzaC and Gal1 on cell growth and phenotype was determined on the Burkitt lymphoma cell line BL36. An immunocytochemical analysis for detection of Gal1 protein expression was performed in AzaC-treated cells. To investigate the direct effects of Gal1, recombinant Gal1 was added to cells.

Results: Treatment of lymphoid B cells with AzaC results in: i) a decrease in cell growth with an arrest of the cell cycle at G0/G1 phase, ii) phenotypic changes consistent with a differentiated phenotype, and iii) the expression of p16, a tumor-suppressor gene whose expression was dependent of its promoter demethylation, and of Gal1. A targeting of Gal1 to the plasma membrane follows its cytosolic expression. To determine which of the effects of AzaC might be secondary to the induction of Gal1, recombinant Gal1 was added to BL36 cells. Treated cells displayed growth inhibition and phenotypic changes consistent with a commitment toward differentiation.

Conclusions: Altered cell growth and expression of the cell surface plasma cell antigen, CD138 are detectable in BL36 cells treated by AzaC as well as by Gal1. It seems that AzaC-induced Gal1 expression and consequent binding of Gal1 on its cell membrane receptor may be, in part, involved in AzaC-induced plasmacytic differentiation.
Introduction
DNA methylation is involved in cellular development, differentiation and transformation [1]. In different types of tumours, aberrant methylation of CpG islands in the promoter region has been observed for many differentiation- and cancer-related genes resulting in the silencing of their expression [2]. Therefore, over the past decade, there has been increasing interest in the use of demethylating agents to induce the differentiation or the apoptosis of cancer cells [3,4]. Treatment of the cells with the pyrimidine analogue 5-AzaCytidine (AzaC), which inhibits methylation of cytosine residues during replication in the newly synthesised DNA, has been demonstrated to reactivate the expression of many silenced genes, as well as the expression of the silenced retro viral genomes [5]. Silencing of one of the most important cell cycle regulatory proteins p16INK4a by methylation of the CpG islands in the promoter region has been found to be a common event in tumours [6,7]. Protein p16 suppresses S-phase entry by antagonising the cyclin-dependent kinases CDK4 and CDK6 [8].

Deciphering the molecular mechanisms underlying the phenotypic effects of the treatment with demethylating drugs is a crucial step in understanding what genes may be interesting targets for chemotherapy. The available data on the mechanism of action of these drugs strengthen the idea that it is different from that of agents that act primarily via their cytotoxic effects, such as Arc-C [9]. Several lines of evidence suggest that galectin-1 (Gal-1), a 14 kDa galactoside-binding protein distributed widely in immune cells, could be involved in these mechanisms. Several members of the galectin family have been found to modulate cell differentiation and cell survival [10–15]. Early studies demonstrated that the expression of Gal1 could be induced in cultured hepatoma-derived cells by treatment with AzaC [16]. Chiariotti and co-workers showed that reactivation of the silent Gal1 alleles is accompanied by a transition from a fully methylated to a fully unmethylated state of several CpG dinucleotides in the promoter region [17]. In addition, nonexpressing tissues exhibited highly heterogeneous methylation profiles [18]. Gal is considered to be a typical cytosolic protein, lacking a signal peptide for membrane translocation [19]. However, most of the functions assigned to galectins are confined to the cell surface or extracellular milieu [10,20,21], consistent with evidences for extracellular roles of Gal1 in regulation of cellular differentiation and proliferation. It is clear that Gal1 can be specifically secreted and targeted by an infrequent mechanism [22–24]. The constitutive expression as well as the secretion of Gal1 dramatically depend on cell types [25] and are responsive to developmental events [20,22,23].

An example is found during erythroid differentiation of the K562 human leukaemia cell line. During differentiation induced by erythropoietin and deprivation of granulocyte-macrophage colony-stimulating factor, the cells empty their cytoplasmic content of endogenous Gal1 into the external medium where it is bind to cell surface receptors [24]. The synthesis and secretion of Gal1 by leukocytes are of interest because lactosaminoglycans present at the leukocyte cell surface may be physiologically significant galectin receptors that could mediate autocrine or paracrine functions. Several lines of evidence indicate that Gal1 may function as an autocrine negative growth regulator or as a pro-apoptotic factor [26–28]. We have recently demonstrated that Gal1 binding to Burkitt lymphoma cells results in an intracellular signal, with inhibition of the tyrosine phosphatase activity of CD45 and therefore phosphorylation of Lyn kinase [29,30].

In this work, we study the effect of AzaC treatment on the lymphoma cell line BL36. As p16INK4a gene has been found to be downregulated by hypermethylation at high frequency in different types of tumours [6,7], it is used as a control of AzaC effect. Then, the phenotypic effects of AzaC are compared to those obtained by the addition of exogenous Gal1. The findings that we report here lend further support to a potential role for Gal1 in the AzaC-induced pathway of differentiation in hematopoietic cells.

Materials and Methods
The BL36 B lymphoma cell line [31], a gift from Pr. Lenoir (CIRC, Lyon, France) to Pr. M. Raphael, was maintained in a complete medium of RPMI 1640, containing 10% heat-inactivated foetal calf serum, 2 mM L-Glutamine, 1 mM sodium pyruvate (complete medium). Treatment with AzaC was conducted as follows: 24 hours after seeding 5, 10 or 50 µM of AzaC were added to 5 ml of complete medium [16,32]. The cells were feded with the appropriate medium during the time of the experiments.

Several independent methods were used to assess the proliferative versus death states of the cells. For direct determination of cell number, at the indicated time point the cells were harvested and counted using a Coulter Counter (Beckman Coulter France, Villepinte, France). Determination of the viable cell numbers used propidium iodide (PI) (Sigma, Saint-Quentin Fallavier, France). To determine the percent cell death including both apoptotic and necrotic cells, AzaC-treated cells were analyzed for AnnexinV binding and PI uptake as described [33] using the ApoDetect AnnexinV-FITC kit (Zymed). Briefly, after washing of cultured cells (3.10^5) with PBS and resuspension in binding buffer, the cells were stained with 10 µl FITC-labelled AnnexinV and 10 µl PI (20 µg/ml). After 5 min of incubation at room temperature in the dark, again 200 µl of binding buffer was added and cells were ana-
lyzed by flow cytometry. The percent cell death was calculated by determining the percent of viable cells:
\[
\text{% viable} = \frac{\text{Annexin}^\text{V}^-, \text{P.I.}^-, \text{treated cells} \times 100}{\text{Annexin}^\text{V}^-, \text{P.I.}^-, \text{untreated cells}}
\]

The MTS assay (CellTiter 96™, Promega, Charbonnières, France) [34] was used to compare the percentage of metabolically active cells in treated cells vs. untreated cells, as previously described [14]. To study the cell cycle, 2.10^6 BL36 cells were pelleted at 1000 g for 5 minutes and the pellet was incubated in a mixture of ethanol-PBS (70/30 v/v). The cells were pelleted another time and suspended in 800 µl PBS. One hundred microliters of 1 mg/ml RNase A was added to the cell suspension. One hundred microliters of 400 µg/ml PI was added to the solution to stain the nuclear DNA. The DNA content of the cells was determined by a flow cytometer, FACScan (Becton Dickinson, Mountain View, CA), and the percentages of cells in G0+G1, S, and G2+M phases of the cell cycle were analyzed by a polynomial model (SFT, Becton Dickinson).

To determine the cell phenotypes, cells were suspended in PBS supplemented with 2% BSA, and incubated in suspension for 30 min with the fluorescently tagged primary antibody or negative control, or incubated with untagged antibody, washed, and incubated again for 30 min with FITC-conjugated secondary antibody. All incubations were performed at 4°C. Flow cytometry was performed using a Coulter Epics Elite ESP instrument.

Human recombinant Gal1 (rGal1) was obtained as described elsewhere [14]. The protein was purified by affinity chromatography on a lactosyl-divinylsulfone-agarose column. Antibodies against human Gal1 were generated as described in [35] and [36]. The immunolocalization of Gal1 was carried out as described for K562 cells [24].

For the preparation of cell extracts, a total of 17.10^6 cells were solubilized in 1 ml of extraction buffer: 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.1% SDS (w/v), 0.5% sodium deoxycholate (w/v), 0.5% Nonidet NP40 (v/v). Finally, 1 tablet of antiprotease cocktail (Roche, Meylan, France) was added to 10 ml of buffer. The cells were sonicated in ice three times. The lysate was centrifuged at 100,000 g for 15 min at 4°C. The supernatant was collected and stored at -20°C until used. Proteins were resolved by discontinuous SDS-PAGE on 1.5 mm gel (T: 6–18%) according to the method of Laemmli. [37]. For Western blotting, proteins separated by SDS-PAGE were electrotransferred onto Immobilon-P membrane (Millipore). Blots were incubated with 1:50 anti-Gal1 mAb, or 1:500 anti-pl6 mAb (Pharmingen) for 2 h at room temperature. The blots were developed with anti-mouse Ig antibody-HRP diluted 1/10,000, followed by incubation in the Amplified Opti-4CN kit substrate (Bio-Rad). The image of the membranes was acquired from GS-700 Densitometer 4, and analyzed with Molecular Analyst Software (Bio-Rad).

**Results**

During the four days of treatment with AzaC, cell proliferation appeared to slow (Fig. 1A). When BL36 cells were cultured with AzaC at the high concentration of 50 µM, cell proliferation was strongly inhibited. BL36 cells exposed to 5 µM AzaC also exhibited a significant reduced growth rate but these cells were >95% viable by propidium iodide test even at day 4 (data not shown), and were found metabolically active by MTS assay as described below. According to these results, the following experiments addressing metabolic activity, death, and cell differentiation were performed.

The proportion of metabolically active cells was determined using the MTS test in cultures treated with AzaC in comparison with untreated cells (Fig. 1B). The cellular conversion of MTS to the ultraviolet-absorbing formazan product has been demonstrated to be directly proportional to cellular metabolism resulting in the formation of reducing equivalents such as NADH or NADPH [38]. A drop in the % of metabolically active cells of about 36% was observed over the 24 h period following the addition of 10 µM AzaC, and went up to 42% in cells treated with 50 µM AzaC. Cell death was confirmed by an increase in annexinV/PI staining (Fig. 2). Within 48 h of incubation with AzaC at 10 µM, the number of AnnexinV+ PI+ apoptotic cells and AnnexinV− PI+ necrotic cells increased. For longer incubation times, induced cell death increased dramatically.

Studies investigating the mechanisms whereby B lymphoma cells are induced to undergo apoptosis demonstrated that an arrest in the cell cycle preceded apoptosis [39]. To determine whether AzaC modified the cell cycle distribution of BL36 cells, the DNA content of AzaC-treated cells was analyzed by PI staining. Cells were exposed to 10 µM AzaC for 2, 4 and 7 days. After 7 days, AzaC-treated cells exhibited a relative increase of cells in G0/G1 (77%) in comparison with controls (56%). In the same time, the percentage of cells in the S phase compartment drops from 38 to 18%, suggesting an accumulation of cells into the G1 phase of the cell cycle (Fig. 3). However, there was no change in the relative cell cycle distribution at 2 or 4 days after AzaC treatment. By this time, a significant population of cells has undergone apoptosis. This suggests that, at least during the first days of treatment, inhibition of growth is uncoupled with an arrest in the cell cycle.
Figure 1
Effect of AzaC and Gal1 on growth and viability of BL36 cells in culture. A. The cells were seeded at $4 \times 10^5$/ml and exposed to AzaC at various concentrations for zero to 4 days. Cells were counted every day on a Coulter Counter. B. Cells were cultured in triplicate in the presence or absence of AzaC. Metabolic activity was measured at the indicated times by the MTS assay. Results are given as mean percentage of metabolically active cells (%) in cells grown in the presence of AzaC compared to cells grown in the absence of AzaC. C. Cells grown in the presence of various concentrations of Gal1 were compared to control cells. The data represent the mean of 3 experiments.
The effects of different concentrations of AzaC (5, 10, and 50 µM) on the expression of various surface antigen of BL36 cells were investigated. AzaC increased the cell population that expressed the cell-surface maturation marker CD23, CD30 present on activated B-lymphocytes [40] and CD138 (Syndecan-1). After the treatment with 50 µM

Figure 2
Induction of cell death in cells treated by either AzaC or rGal1. The BL36 cell line was treated with 10 µM AzaC, 700 nM rGal1, or buffer control and the percent cell death was evaluated by annexinV/propidium iodide staining, as described in "Materials and Methods". There is a dramatic increase in annexinV+/propidium iodide− cells in the BL36 samples treated with AzaC, not seen with the cells treated with Gal1.
Figure 3
Cell cycle analysis of AzaC-treated and control cells. The BL36 cells were incubated for 7 days in the presence of 10 µM AzaC and the DNA contents were measured.
AzaC some changes were observed that were not detected at lower concentrations: an increase of the cell population that expressed CD21, and a decrease of the cell population that expressed CD19 that is lost on maturation to plasma cells [41], and CD71 that is expressed on proliferating cells [42] (Table 1).

P16 is a biochemical marker of cell cycle progression [43] and is also commonly utilized as a marker of demethylation reaction [44]. Consequently, we examined the effects of AzaC treatment on expression of p16 in BL36 cells. As expected, when these cells were treated with AzaC for 48 h, we detected the presence of p16 by Western Blotting (Fig. 4A). Thus, taken together the data showed that AzaC treatment induced an inhibition of cell growth related to an arrest at G0/G1 phase of the cell cycle, and confirmed the efficiency of AzaC treatment for expressing the tumour suppressor gene p16.

To determine whether AzaC is able to induce the expression of Gal1 in B lymphoma cells, protein extracts prepared form cells treated with 5–10 µM AzaC and from untreated cells were separated by SDS-PAGE and analyzed by immunoblotting with anti-Gal1 antibody. Fig. 4B,C shows the rate of variation in Gal1 expression induced by the differentiating agent. The galectin was not detected either in untreated BL36 cells or BL36 cells treated with AzaC for 24 or 48 h. The galectin became detectable in AzaC-treated cells by 96 h. Then, to determine whether the newly synthesised galectin molecules in AzaC-treated BL36 cells are expressed on the cell surface, the binding of anti-Gal1 Ab to untreated and treated BL36 cells was studied by immunocytochemistry. To visualize only extracellular Gal1, cultures of BL36 cells were incubated with anti-Gal1 antibody without permeabilization of their membranes. Over the 4-day time-course, AzaC-induced Gal1 did progressively localise to the cell surface. However, Gal1 did not exclusively localise to the cell surface but was also distributed throughout the cytoplasm (Fig. 5).

Several of the changes in AzaC-treated BL cells might be attributed directly to Gal1 induction, as Gal1 has been implicated in differentiation and growth inhibition [11–13,29,45,46]. A series of experiments were thus performed to address whether changes observed in BL36 were direct AzaC effects and/or secondary effects related to Gal1 expression induced by AzaC treatment. To this end, BL36 was treated with recombinant Gal1 (rGal1). Slower growth rates were confirmed for the rGal1-treated cultures. A drop in the % of metabolically active cells of about 28% was observed over the 24 h period following the addition of 700 nM rGal1. However the proportion of metabolically active cells in cultures treated with rGal1 vs. the proportion in untreated cultures was not modified after 4 days of treatment (Fig. 1C). Moreover the variation of cell death detected in treated-cells relative to the control cultures was discrete (<10%) and limited to the first day after the treatment (Fig. 2). To determine whether the inhibition of proliferation could be correlated to a modified phenotype, the effects of 700 nM rGal1 on the expression of various surface antigens shown to be modified or not by AzaC were investigated. The populations of cells that expressed CD19, CD23, CD45RO and CD45RA were unchanged. On the other hand, 24 h rGal1 treatment increased the cell population expressing CD138 (Fig. 6), a marker for plasma cells, while it decreased the expression of CD71. These modifications were reinforced after 48 h rGal1 treatment (Table 2).

**Table 1: Modulation of surface Markers on BL36 Cells by AzaC**

| Surface marker | Control | Treatment AzaC = 5 µM | AzaC- 10 µM | AzaC = 50 µM |
|----------------|---------|----------------------|-------------|-------------|
| CD 19          | 94.9    | 88.5                 | 86.1        | 58.1        |
| CD 21          | <20     | <20                  | <20         | 20.3        |
| CD 23          | 31.5    | 47.6                 | 45.2        | 63.8        |
| CD 30          | <20     | <20                  | 48.4        | 21.5        |
| CD 45 RA       | 76.7    | 74.4                 | 71.2        | 64.6        |
| CD 45 RO       | 21.4    | 35.1                 | 33.3        | 38.5        |
| CD 71          | 97.3    | 94.9                 | 93.8        | 83.8        |
| CD 138         | <20     | 23.9                 | 23.8        | 24.8        |

BL36 cells were exposed with 5 µM, 10 µM and 50 µM AzaC for 4 days. Then cell surface antigens were analyzed by flow cytometry. Values below 20% were considered as negative. In the same conditions, CDs 3 and 10 remain negative, and no variability was observed for CDs 11 a, 18, 25, 38, 44, 48, 54, 58, 77, 80, and 95.
Figure 4
Immunoblotting of p16 and Gal1 from extracts of BL36 treated by AzaC. After different periods of treatment by AzaC, cell extracts were separated by SDS-PAGE, followed by electrophoretic transfer onto Immobilon-P membranes and immunostaining with (A) anti-p16, or (B) anti-Gal1 monoclonal antibodies. Hela cells extract and rGal1 were used as positive controls for p16 and Gal1, respectively. (C) Representation of the variation of Gal1 expression in cells treated different times with 5 or 10 mM AzaC, using the analysis of the Western blots in Molecular Analyst software.
been shown to affect similar cell processes in cancer cells, including differentiation, and growth inhibition [12–15,27,29,46–51]. Available data are consistent with the suggestion that the expression of Gal1, accompanied by its secretion and its binding to cell surface receptors, could be involved in the AzaC observed effects in hematopoietic cells where Gal1 modulates differentiation or apoptosis. However, the mechanisms of these effects on hematopoietic cells are unclear yet.

In the present study, the effects of AzaC, on the cell phenotype, cell differentiation and cell death of BL36 cells were analyzed. The effects on cellular growth were time- and dose-dependent. Five μM AzaC caused significant inhibition on cellular growth, but the cell viability remained practically unchanged. AzaC increased the cell fraction in the G0/G1 phases, suggesting that AzaC inhibits cell division, which may be one of critical mechanisms of cell modulation by AzaC. AzaC-treated cells initially may become arrested at the G1 phase and then may either escape to the cycle arrest or die due to mechanisms leading to programmed cell death.

We also show that incubation of BL36 with AzaC induces expression of Gal1. AzaC is thought to exert its effects as a competitive inhibitor of cytosine methylation, resulting in the expression of silenced genes. The gene for Gal1 is one whose expression is possibly enhanced in this manner. In the results reported here, we found that Gal1 was detected in cytosol after 120 h of treatment by 10 μM AzaC and then Gal1 was externalized and bound to cell surface receptors 24 h later. A key to understanding the extracellular biological functions of Gal1 is how its secretion appears to be regulated and re-directed during development and differentiation. Gal1 is likely released form vesicles close to the plasma membrane. On the basis of the data, we propose that the released Gal1 be immediately recruited to modulate cell activity. Gal1 may do this by interacting with and modulating cell receptors via its carbohydrate recognition domains because the Gal1-receptor interaction is abrogated by thiodigalactoside [29].

Others and we have previously reported that Gal1 binds to T and B lymphoblastoid cells [29,52,53]. Other studies have demonstrated that galectins are immunosuppressive,

| Treatment by AzaC: | 5 days | 6 days | 7 days |
|--------------------|--------|--------|--------|
| Control            | ![Image](image1.png) | ![Image](image2.png) | ![Image](image3.png) |
| Permeabilized cells| ![Image](image4.png) | ![Image](image5.png) | ![Image](image6.png) |
| Nonpermeabilized cells | ![Image](image7.png) | ![Image](image8.png) | ![Image](image9.png) |

**Figure 5**
Immunoreactive localization of Gal1 in AzaC-treated BL36 cells. Cytospins were incubated with anti-Gal1 serum and peroxidase-stained (original magnification 1250×). First line: negative controls performed on untreated BL36 cells. No Gal1 was detectable with anti-Gal1 antibody. Second line: permeabilized cells treated cells stained with monospecific anti-Gal1 antibody; arrows indicate the localization of Gal1. Third line: after 144 h, Gal1 was detectable on the cell surface of nonpermeabilized cells. No immunostaining was observed with controls performed with preimmune serum (not shown).
in animal models of autoimmune diseases [54–56]. Whereas the full role of Gal1 in modulating immune function is not yet understood, the increase in Gal1 expression by AzaC in BL cells suggests that Gal1 may play a role in the behaviour of normal leukocytes and of tumour cells.

What is the underlying mechanism? Although the regulatory machinery triggered by demethylating stimulus and resulting in phenotype modifications is not yet elucidated, it probably involves the stimulation of a signalling cascade that regulates cell proliferation and viability. A recently proposed model for such a cascade suggests the involvement of a cytoplasmic protein, AZ2 [57]. The amino-terminal part of the AZ2 protein is homologous to the previously reported TANK and I-TRAF, which participate in the signal transduction cascade from the TNF-receptor to the transcription factor NFkappaB. Demethylating stimulus may also modify a pathway activated by the membrane-anchored protein-tyrosine phosphatase CD45. Engagement of CD45 is known to regulate Src tyrosine kinases phosphorylation, phospholipase C$\gamma$ regulation, inositol phosphate production, diacylglycerol production, PKC activation, and calcium mobilisation [58–60].

Increased synthesis and secretion of Gal1 by the cell could account for part of the phenotypic alterations detected in AzaC treated cells. Gal1-induced dimerisation and/or segregation might inhibit the catalytic site in CD45, thereby

---

**Figure 6**
Modification of the expression of CD138 in rGAL1-treated cells. Cells incubated for 24 or 48 h with rGal1 (700 nM) were stained with anti-CD138 antibody and analyzed by flow cytometry. Controls were performed in the absence of rGAL1. Representative histograms: x-axis, log of the fluorescence intensity; y-axis, number of events.

---

**Table 2: Modulation of Surface Markers on BL36 Cells by rGal1**

| Surface Marker | Control 24 h | Treatment (% positive) rGal1 – 24 h | Control 48 h | Treatment (% positive) rGal1–48 h |
|----------------|-------------|------------------------------------|-------------|----------------------------------|
| CD71           | 98.00       | 94.90                              | 93.00       | 45.00                            |
| CD138          | <20         | 20.20                              | 25.00       | 70.00                            |

BL36 cells were exposed with 700 nM rGal1 for 1 and 2 days. Then cell surface antigens were analyzed by flow cytometry. Values below 20% were considered as negative.
blocking tyrosine phosphates activity. Because Gal1 binding to cell surface receptors results in tyrosine phosphorylation [29,61], it may allow a kinase-dependent signal to be transduced. Several studies have linked Gal1 expression with growth inhibition [27] and cell death [26,62]. However, the reports that some growth inhibitory agents did not induce Gal1 expression indicated that Gal1 expression is not dependent on the cell's growth state in general, through it may be involved in growth suppression [63]. Moreover, it is likely that Gal1 acts in a manner to regulate specific signal transduction processes that is determined by the cell type and by the state of cell differentiation. In this work, exogenous rGal1 added to BL cells inhibited cell growth. Moreover, Gal1 as well as AzaC induced an expression of the cell surface plasma cell antigen, CD138, a phenotypic marker that identify cells with plasmacytic differentiation [64]. This is consistent with the hypothesis that AzaC and Gal1 share similar signals for differentiation, however, since there was a significant difference in the expression of CD19 and CD23 after AzaC or Gal1 treatments it is likely that some pathways are specifically modified by AzaC. The mechanisms involved in these different pathways, important in clinical therapy, remain to be elucidated in the future. Ongoing studies are aimed at identifying as globally as possible the modifications resulting from AzaC treatment by using proteomics [65].

Acknowledgements

This work was supported, in part, by grants from the Ministère de l’Education Nationale de la Recherche et de la Technologie (MENRT), and from the Ligue Française contre Le Cancer (Comité de Seine Saint-Denis). FP was supported by ARC (Association pour la Recherche sur le Cancer).

References

1. Schmutte C, Jones PA: Involvement of DNA methylation in human carcinogenesis. Biol Chem 1998, 379:377-388
2. Momparler RL, Bovensieb V: DNA methylation and cancer. J Cell Physiol 2000, 183:145-154
3. Murakami T, Li X, Gong J, Darzynkiewicz Z: Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res 1995, 55:3093-3098
4. Wang XM, Wang X, Li J, Evers BM: Effects of 5-azacytidine and butyrate on differentiation and apoptosis of hepatic cancer cell lines. Ann Surg 1998, 227:922-931
5. Masucci MG, Contreras-Salazar B, Ragni E, Falk K, Minarovits J, Bennewitz J, Klein G: 5-Azacytidine up regulates the expression of EBV nuclear antigen 2 (EBNA2) through ENBNA6 and latent membrane protein in Burkitt’s lymphoma line rael. J Virol 1989, 63:3135-3141
6. Okamoto A, Demetriuk DJ, Spillare EA, Hagikawa K, Hussain SP, Bennewitz WP, Forrester K, Herwig B, Serrano M, Beach DH, et al: Mutations and altered expression of p63/4NK in human cancer. Proc Natl Acad Sci USA 1994, 91:11045-11049
7. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: CpG island methylation is associated with transcriptional silencing of the tumour suppressor p63/p73 in human cancers. Nat Med 1995, 1:686-692
8. Singar R, Ginder GD: DNA methylation. Blood 1999, 93:4059-4070
9. Luebbern M: DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes, and lymphoproliferative diseases and possible mechanisms of action. Curr. Top. Microbiol. Immunol 2000, 249:135-164
10. Hadari YR, Arbel-Goren R, Levy Y, Amsterdam A, Ron R, Zakut R, Zick Y: Galectin-3 binding to integrins inhibits cell adhesion and induces apoptosis. J Cell Sci 2000, 113:135-139
11. Adams L, Scott GK, Weinberg C: Biphasic modulation of cell growth by recombinant human galectin-1. Biochem. Biophys. Acta 1996, 1312:137-144
12. Allione A, Wells V, Forni G, Mallucci L, Novelli F: Beta-galactoside-binding protein (beta GBP) alters the cell cycle, up-regulates expression of the alpha- and beta-chains of the IFN-gamma receptor, and triggers IFN-gamma-mediated apoptosis of activated human T lymphocytes. J Immunol 1998, 161:2114-2119
13. Blaser C, Kaufmann M, Muller C, Zimmermann C, Wells V, Mallucci L, Pericher H: Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur. J. Immunol 1998, 28:2311-2319
14. Fouillot M, Lévi-Strauss M, Giudicelli V, Lutomska D, Bladier D, Caron M, Joubert-Caron R: Affinity purification and characterization of recombinant human galectin-1. J. Chromatogr 1998, 706:167-171
15. Perillo NL, Marcus ME, Baum LG: Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J. Mol. Med 1998, 76:402-412
16. Chiariotti L, Benvenuto G, Zarrilli R, Rossi E, Salvatore P, Calabuoni V, Bruni CB: Activation of the galectin-1 (L-14-I) gene from nonexpressing differentiated cells by fusion with undifferentiated and tumorigenic cells. Cell Growth Diff 1994, 5:769-775
17. Benevenuto G, Carpentieri M, Salvatore P, Cindolo L, Bruni CB, Chiariotti L: Cell-specific transcriptional regulation and reactivation of Galectin-1 gene expression are controlled by DNA methylation of the promoter region. Mol. and Cell. Biol. 1996, 16:2736-2743
18. Salvatore P, Benevenuto G, Caporaso M, Bruni CB, Chiariotti L: High resolution methylation analysis of the galectin-1 gene promoter region in expressing and nonexpressing tissues. FEBS Lett 1998, 421:152-158
19. Bladier D, Le Caer J-P, Joubert R, Caron M, Rossier J: β-galactoside soluble lectin from human brain: a complete amino acid sequence. Neurochem. Int 1991, 18:275-281
20. Hughes RC: Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999, 1473:173-175
21. Mehul B, Hughes R: Plasma membrane targeting, vesicular budding and release of galectin 3 from the cytoplasm of malignant cells during secretion. J. Cell Sci 1997, 110:1169-1178
22. Cooper DNW, Barondes SH: Evidence for export of a muscle lectin from cytoplasm to the Golgi apparatus and for a novel secretory mechanism. J. Cell Biol 1990, 110:1681-1691
23. Avellana-Adalid V, Rebel G, Caron M, Cornillot P, Caron M, Joubert-Caron R: Changes in S-type lectin localization in neuroblastoma cells (NIE115) upon differentiation. Glycoconjug J 1994, 11:286-291
24. Lutomska D, Denize N, Mellot-Detaxe D, Bourin P, Pontet M, Bladier D, Caron M, Joubert-Caron R: Differential expression of a β-galactoside binding lectin (galectin 1) in human erythroblademia cell lines: TF1 and KSB2 and for a novel variant in human malignant T cells. Fund. din. Immunol 1995, 3:66
25. Lutomska D, Denize N, Mellot-Detaxe D, Bourin P, Pontet M, Bladier D, Caron M, Joubert-Caron R: Differential expression of a β-galactoside binding lectin (galectin 1) in human erythroblademia cell lines: TF1 and KSB2. Blood 1996, 88:118B
26. Goldstone SD, Lavin MF: Isolation of a cDNA clone, encoding a human β-galactoside binding protein, overexpressed during glucocorticoid-induced cell death. Biochem. Biophys. Res. Comm 1991, 178:746-750
27. Wells V, Mallucci L: Identification of an autocrine negative growth factor; mouse β-galactoside-binding protein is a cytokine-like factor and cell growth regulator. Cell 1991, 64:91-97
28. Allione A, Bernabei P, Rigamonti L, Bertolaccini L, Mallucci L, Forni G, Novelli F: Differential IFN-γ expression controls the growth of human malignant T cells. Fund. din. Immunol 1995, 3:66
29. Fouillot M, Joubert-Caron R, Poirier F, Bourin P, Monostori E, Levi-Strauss M, Bladier D, Caron M: Regulation of CD45-in-induced signaling by galectin-1 in Burkitt lymphoma B cells. Glycobiology 2000, 10:413-419
30. Fouillit M, Poirier F, Monostori E, Raphael M, Bladier D, Joubert-Caron R, Caron M: Analysis of galectin 1-mediated cell signaling by combined precipitation and electrophoresis techniques. Electrophoresis 2000, 21:275-280

31. Favrot MC, Maritaz O, Suzuki T, Cooper M, Philip I, Philip T, Lenoir G: EBV-negative and -positive Burkitt cell lines variably express receptors for B-cell activation and differentiation. Int J Cancer 1998, 80:101-906

32. Cuomo L, Triverdi P, de Campos-Lima PO, Zhang QJ, Ragnar E, Klein G, Masucci MG: Selective induction of allostimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative Burkitt lymphoma cell lines. Mol Immunol 1993, 30:441-450

33. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994, 84:1415-1420

34. Buttke TM, McCubrey JA, Owen TC: Use of an aqueous soluble annexin V conjugate to measure viability and proliferation of lymphomah-dependent cell lines. J Immunol Meth 1993, 157:233-240

35. Joubert R, Kuchler S, Zanetta JP, Bladier D, Avellana-Adalid V, Caron M, Doineel C, Vincendon G: Immunohistochemical localization of β-galactoside-binding lectin in rat central nervous system. I. Light and electron-microscopic studies in developing cerebral cortex and corpus callosum. Dev Neurosci 1989, 11:397-413

36. Cornillot JD, Pontet M, Dupuy C, Chaddi A, Caron M, Joubert-Caron R, Bourin P, Bladier D: Production and characterization of a monoclonal antibody able to discriminate galectin-1 from galectin-2 and galectin-3. Glycobiology 1998, 8:425-432

37. Laennmi UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970, 227:680-685

38. Berridge MV, Tan AS: The CD19/CD21 signal transduction complex of B lymphocytes. J Exp Med 1986, 164:155-164

39. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, R , Bou r i n P , B la d ie r D: Production and characterization of a new regulatory motif in cell-membrane glycoprotein on tumor cell lines. Mol Immunol 1981, 18:451-459

40. Berridge MV, Tan AS: Expression of galectin-1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors. Int J Cancer 1994, 57:17-184

41. Tedder TF, Zhou LJ, Engel P: Synthesis of an endogeneous lectin, galectin-1, by human endothelial cells is up-regulated by galectin-1. J. Exp. Med. 1993, 178:451-459

42. Scott DW, Livnat D, Pennell CA, Keng P: Isolation of the novel cDNA of a gene of which expression is enhanced by galectin-1. Glycobiology 1998, 8:425-432

43. Berridge MV, Tan AS: Effect of 5-aza-2′-deoxycytidine and vitamin D3 analogs on growth and differentiation of human myeloid leukemic cells. Cancer Chemother Pharmacol 1998, 41:275-280

44. Bender CM, Pao MM, Jones PA: Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits. Eur J Immunol 1981, 11:500-507

45. Chiariotti L, Berlingieri MT, Battaglia C, Benvenuto G, Martelli ML,ழர் G, Masucci MG: Characterization of the CD19/CD21 molecule: a new cytokine receptor of the tumor cell lines. J Immunol Meth 1995, 190:27-34

46. Izaguirre MM, Rabinovich GA, Ivanovic V, Sotomayor C, Wolfsen-Todel C: Galectin-1 from ovine placenta – amino-acid sequence, physicochemical properties and implications in T-cell death. Int J Cell Biol 1999, 1:121-128

47. Dore BT, Chomienne C, Momparrer RL: Effect of 5-aza-2′-deoxycytidine and vitamin D3 analogs on growth and differentiation of human myeloid leukemic cells. Cancer Chemother Pharmacol 1998, 41:275-280

48. Zinzar S, Silverman LR, Richardson EB, Bekesi G, Holland JF: Azacytidine plus verapamil induces the differentiation of a newly characterized biphenotypic human myeloid-B lymphoid leukemic cell line BW-90. Leuk Res 1998, 22:677-685

49. Ahmed H, Sharma A, DiCiccoio RA, Allen HJ: Lymphoblastoid cell adhesion mediated by a dimeric and polymeric endogenous beta-galactoside-binding lectin (galactapin). J. Mol. Recognit 1992, 5:1-8

50. Baum LG, Seilhamer JJ, Pang M, Levine WB, Beydon D, Berliner JA: Anti-CD2 molecules: a new receptor system for galectin-1, by human endothelial cells is up-regulated by endothelial cell activation. Glycoconj J 1995, 12:63-68

51. Levy G, Tarrab-Hazdai R, Teichberg VI: Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits. Eur J Immunol 1981, 11:500-507

52. Offner H, Celnik B, Bringman TS, Casentini-Borocz D, Nedwin GE, Vanderba AA: Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. J. Neuroimmunol 1990, 28:77-81

53. Rabinovich GA, Daly G, Dreja H, Tailor R, Riera CM, Hirabayashi J, Chernajovsky Y: Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J. Exp Med. 1999, 189:57-67

54. Miyagawa J, Muguruma M, Aoto H, Suetake I, Nakamura M, Tajima S: Isolation of the novel cDNA of a gene of which expression is induced by a demethylating stimulus. Gene 1999, 240:289-295

55. Biffen M, McMichael-Phillips D, Larson T, Venkitaraman A, Alexander D: The CD45 tyrosine phosphatase regulates specific pools of antigen receptor-associated p59 lyn and CD4-associated p56 lck tyrosine in human T-cells. EMBO J 1994, 13:1920-1929

56. Katagiri T, Ogimoto M, Hasegawa K, Mizuno K, Yskura H: Selective regulation of Lyn tyrosine kinase by CD45 in immature B cells and monocytic leukemia cell line. J. Biol Chem 1995, 270:2798-27990

57. Weiss A, Schlessinger J: Switching signals on or off by receptor dimerization. Cell 1998, 94:277-280

58. Yespa GNR, Lewis LA, Kozak KR, Moran M, Nguyen JT, Lam B, Carrie McIcell MC: Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J Immunol 1999, 162:799-806

59. Perlillo N, Pace KE, Seilhamme JJ, Baum LG: Apoposis of T-cells mediated by galectin-1. Nature 1995, 378:736-738

60. Gillenwater A, Xu XC, Estrov Y, Sacks PG, Lotan D, Lotan R: Modulation of galectin-1 content in human head and neck squamous carcinoma cells by sodium butyrate. Int J Cancer 1998, 75:217-224

61. Kopper L, Sebestyen A: Syndecans and the lymphoid system. Leuk Lymphoma 2000, 38:271-281

62. Poirier F, Pontet M, Labas V, le Caer JP, Sghioaur-Iman L, Raphael M, Caron M, Joubert-Caron R: Two-dimensional database of a Burkitt lymphoma cell line (DG 75) proteins: protein pattern changes following treatment with 5′-azacytidine. Electrophoresis 2001, 22:1867-1877